03 June 2004 : Original article
How about the effect of thiazolidinediones in diabetic nephropathy?
Keisuke InaMed Sci Monit 2004; 10(6): LE7-7 :: ID: 16409
Abstract
Dear Editor, The metabolic effects of insulin and rosiglitazone combination therapy in Chinese Type 2 diabetic patients with nephropathy I am afraid that thiazolidinedione (TZD) could not stastically ameliorate lipid metabolism in type 2 diabetic patients with nephropathy. As to the effect of TZD on diabetic nephropathy, I would like to offer a comment. It has been reported that TZD had the renoprotective effect, containing attenuation of glomerular hyperfiltration and decrease of urinary albumin excretion rate(UAE) in experimental diabetic rats as well as diabetic patients [1–3], as the author would mention in the present article. Recently, the mechanism by which TZD improved renal dysfunction was determined [2,4]. TZD was indicated to have the renoprotective effect through inhibiting activation of DAG-PKC-ERK pathway which leaded to renal dysfunction in diabetes. In previous reports, it has been shown that TZD ameliorated microalbuminuria, treated with TZD only or TZD and the angiotensin converting enzyme inhibitor [1–3]. The feature of cases in the present paper is, first, that the degree of nephropathy was moderate or severe, although the level of UAE and the value of glomerular filtration rate were not shown. Second, the angiotensin II receptor blocker (ARB) was treated in all of the patients before combination therapy with TZD. I should like to know the effect of ARB and TZD combination therapy on moderate or severe diabetic nephropathy. The effects of TZD on other organs as well as the fat tissue and the kidney are expected.
Keywords: Albumins - analysis, Diabetic Nephropathies - complications, Diabetic Nephropathies - drug therapy, Diabetic Nephropathies - metabolism, Kidney Diseases - complications, Kidney Diseases - drug therapy, Kidney Diseases - metabolism, Lipid Metabolism, Thiazolidinediones - pharmacology, Thiazolidinediones - therapeutic use, Albumins - analysis, Diabetic Nephropathies - metabolism, Kidney Diseases - metabolism, Lipid Metabolism, Thiazolidinediones - therapeutic use
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952